Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 3Terminated 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasms 2Hematologic Neoplasms 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × Aftercare × Clear all
NCT03943082 2021-11-16

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

University of California, San Francisco

Phase NA Terminated
252 enrolled
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02440737 2019-10-18

NEST

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
67 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡